Pfizer has struck a high-stakes deal with 3SBio to license SSGJ-707, a bispecific antibody targeting PD-1 and VEGF, outside of China. Unlike current drugs that hit only PD-1, this antibody aims at two ...

No patent infringement found in exports of individual conjugate bulk substances and research-use finished products of PCV13 ...

The World Health Organization announced Tuesday it has officially adopted the first-ever "Pandemic Agreement," just as the ...

Pfizer Inc. boosts its oncology pipeline with strategic control of PD-1/VEGF bispecific drugs via 3SBio deal. Click for more ...

The deal comes three months after Pfizer inked a PD-1/VEGF partnership with Summit Therapeutics, leading BMO Capital Markets ...

The largest Chinese licensing deal behind Pfizer’s is Novartis’ partnership with Shanghai Argo Biopharma, worth potentially ...

3SBio will grant Pfizer exclusive global rights, not including China, to develop, manufacture and commercialize SSGJ-707, a ...

Pfizer just penned a $6 billion licensing deal with China's 3SBio to develop and commercialize a cancer drug, SSGJ-707. The ...

At a recent gathering, experts in the Swiss biotech and pharma sector underscored the power of international alliances.